Global Cancer Vaccine Partnering 2012-2018: Deal trends, players, financials and forecasts

Home/Global Cancer Vaccine Partnering 2012-2018: Deal trends, players, financials and forecasts

Global Cancer Vaccine Partnering 2012-2018: Deal trends, players, financials and forecasts

Deals & Alliances (Pharma & Healthcare), Finance & Investment (Pharma & Healthcare), Biotechnology, Healthcare, Prescription Drugs, Pharma & Healthcare Technology, Research & Development (Pharma & Healthcare), Drug Pipeline, Diagnostics, Pharma & Healthcare

Publication ID:

CPA0918001

Publication Date:

September 01, 2018

Pages:

200

Publisher:

Current Partnering

Region:

Global

$2,995.00

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

The Global Cancer VaccinenPartnering 2012-2018: Deal trends, players, financials and forecasts provides comprehensive understanding and unprecedented access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies

Description
The Global Cancer Vaccine Partnering 2012-2018 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cancer vaccine partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer vaccine partnering contract documents
Top cancer vaccine deals by value

This report provides details of the latest Cancer Vaccine agreements announced in the life sciences since 2012.

The report takes the reader through a comprehensive review Cancer Vaccine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Vaccine partnering deals.

The report presents financial deal term values for Cancer Vaccine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Cancer Vaccine partnering field; both the leading deal values and most active Cancer Vaccine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 250 online deal records of actual Cancer Vaccine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Cancer Vaccine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer Vaccine dealmaking since 2012, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Cancer Vaccine deals since 2012. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer Vaccine dealmaking with a brief summary followed by a comprehensive listing of Cancer Vaccine deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Cancer Vaccine partnering deals signed and announced since Jan 2012, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Cancer Vaccine partnering deals signed and announced since Jan 2012. The chapter is organized by specific Cancer Vaccine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Cancer Vaccine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Cancer Vaccine partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer Vaccine technologies and products.

Key benefits

Global Cancer Vaccine Partnering 2012-2018: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

In-depth understanding of Cancer Vaccine deal trends since 2012
Access to headline, upfront, milestone and royalty data
Analysis of the structure of Cancer Vaccine agreements with numerous real life case studies
Detailed access to actual Cancer Vaccine contracts entered into by leading biopharma companies
Identify most active Cancer Vaccine dealmakers since 2012
Insight into terms included in a Cancer Vaccine partnering agreement, with real world examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Cancer Vaccine Partnering 2012-2018: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Cancer Vaccine trends and structure of deals entered into by leading companies worldwide.

Cancer Vaccine Partnering Terms and Agreements includes:

Trends in Cancer Vaccine dealmaking in the biopharma industry since 2012
Analysis of Cancer Vaccine deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Cancer Vaccine deals
Access to Cancer Vaccine contract documents
Leading Cancer Vaccine deals by value since 2012
Most active Cancer Vaccine dealmakers since 2012

In Global Cancer Vaccine Partnering 2012-2018: Deal trends, players, financials and forecasts, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Cancer Vaccine Partnering 2012-2018: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 250 Cancer Vaccine deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Benefits
Global Cancer Vaccine Partnering 2012-2018 report provides the reader with the following key benefits:

Table of Contents

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Cancer Vaccine dealmaking

2.1. Introduction
2.2. Cancer Vaccine partnering over the years
2.3. Most active Cancer Vaccine dealmakers
2.4. Cancer Vaccine partnering by deal type
2.5. Cancer Vaccine partnering by therapy area
2.6. Deal terms for Cancer Vaccine partnering
2.6.1 Cancer Vaccine partnering headline values
2.6.2 Cancer Vaccine deal upfront payments7
2.6.3 Cancer Vaccine deal milestone payments
2.6.4 Cancer Vaccine royalty rates

Chapter 3 – Leading Cancer Vaccine deals

3.1. Introduction
3.2. Top Cancer Vaccine deals by value

Chapter 4 – Most active Cancer Vaccine dealmakers

4.1. Introduction
4.2. Most active Cancer Vaccine dealmakers
4.3. Most active Cancer Vaccine partnering company profiles

Chapter 5 – Cancer Vaccine contracts dealmaking directory

5.1. Introduction
5.2. Cancer Vaccine contracts dealmaking directory

Chapter 6 – Cancer Vaccine dealmaking by technology type

Chapter 7 – Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 – Cancer Vaccine deals by company A-Z

Appendix 2 – Cancer Vaccine deals by stage of development

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 – Cancer Vaccine deals by deal type

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty

Appendix 4 – Cancer Vaccine deals by therapy area

Appendix 5 –Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Cancer Vaccine partnering since 2012
Figure 2: Active Cancer Vaccine dealmaking activity since 2012
Figure 3: Cancer Vaccine partnering by deal type since 2012
Figure 4: Cancer Vaccine partnering by disease type since 2012
Figure 5: Cancer Vaccine deals with a headline value
Figure 6: Cancer Vaccine deals with an upfront value
Figure 7: Cancer Vaccine deals with a milestone value
Figure 8: Cancer Vaccine deals with a royalty rate value
Figure 9: Top Cancer Vaccine deals by value since 2012
Figure 10: Most active Cancer Vaccine dealmakers since 2012
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?

If yes, then please use the form given below and we will get in touch with you immediately.

Kindly use your official email address and contact number to ensure speedy response.

Name *

Email *

Company

Contact Number *

Report Title *

Your Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Drag or click the correct shape to the grey "drop area".